- Open Access
- Open Peer Review
This article has Open Peer Review reports available.
Marketing and clinical trials: a case study
© Francis et al; licensee BioMed Central Ltd. 2007
Received: 30 July 2007
Accepted: 20 November 2007
Published: 20 November 2007
Publicly funded clinical trials require a substantial commitment of time and money. To ensure that sufficient numbers of patients are recruited it is essential that they address important questions in a rigorous manner and are managed well, adopting effective marketing strategies.
Using methods of analysis drawn from management studies, this paper presents a structured assessment framework or reference model, derived from a case analysis of the MRC's CRASH trial, of 12 factors that may affect the success of the marketing and sales activities associated with clinical trials.
The case study demonstrates that trials need various categories of people to buy in – hence, to be successful, trialists must embrace marketing strategies to some extent.
The performance of future clinical trials could be enhanced if trialists routinely considered these factors.
Results from randomised controlled trials (RCTs) make an important contribution to improving patient care. Some trials recruit a large number of patients and involve the collaboration of many doctors, nurses and other healthcare workers around the world. Because trials (especially large trials) can involve a substantial commitment of time and money, it is essential that they address important questions and use rigorous scientific methods. More recently, however, it has been recognised that good management and effective marketing are also essential to enable sufficient numbers of participating centres and patients to be recruited so that the study has enough statistical power . This paper reports a case study of a novel application of a marketing approach from the world of business to a single clinical trial in order to develop a reference model for use in other trials.
Businesses strive to find customers and encourage them to buy what is on offer. Clinical trials strive to find doctors and patients and encourage them to sign up. Thus they face similar challenges and may need to adopt similar approaches to achieve their goals.
Clinical trials progress through distinctive stages, including study design, obtaining funding, finding participants, collecting and processing data, interpreting the results, and reporting. In some stages of a trial the key requirement is to do good science. However, in others the challenge is quite different – the key requirement is to install and operate a range of effective management techniques, similar to those required for marketing a product. Indeed, an experienced trialist observed that a trial is one fifth structure (science) and four-fifths process (i.e. management).
Marketing – the process of finding, winning over and retaining customers – is an important topic in management studies. Marketing has distinctive frameworks, methods and techniques – generally drawn from sociology and social psychology. Marketing became better understood in the 1960s  and now the discipline is ubiquitous within larger companies and many not-for-profit organisations. A definition of marketing by McDonald and Wilson  describes it as "a process for defining markets, quantifying the needs of the customer groups (segments) within these markets, determining the value propositions to meet these needs, communicating these value propositions to all those people in the organisation responsible for delivering them and getting their buy-in to their role, playing an appropriate part in delivering these value propositions to the chosen market segments (and) monitoring the value actually delivered" (pp11). (A value proposition can be defined as a clear statement of the tangible results a customer gets from using the products or services).
The marketing dimension is included only tangentially in the literature on clinical trials . For example, trials are generally stated to need recruitment strategies, use of media and data tracking systems. However, the notion of a developing and working to achieve a formal marketing plan that covers all of the areas in the McDonald and Wilson definition is generally absent from descriptions of trial management.
This is not to suggest that trial managers consider the topic of marketing their trials to potential recruits lightly. Indeed, it is a dominant concern for many trialists. For example, the Diabetic Retinopathy Awareness Program study  undertook many initiatives to recruit volunteers and concluded, "these experiences substantiate the need for a comprehensive coordinated approach, using planned sources, to achieve recruitment success" (pp432). Farrell  has argued persuasively that it is lack of solutions to managerial issues that reduce the effectiveness of trials, and Rowe  suggested that, "to get patients into trials more efficiently pharma companies must begin to think like marketers".
It can be argued that marketing is especially important in clinical trials. Participation in a trial is a formal voluntary act, in that participants need to abide by a set of rules. Accordingly, not only is it necessary for people to volunteer, they also need to sign-up to behave in accordance with a set procedure . In short, participants in a trial (be they clinicians or patients or their families) need to make a commitment, and undertake additional work, often without direct financial benefit to themselves.
Activities within the five stages in marketing a trial
1. To gain the buy-in of the necessary authorities and stakeholders.
2. To gain the buy-in of opinion leaders whose explicit approval provides legitimacy and prestige for the trial.
3. To construct a marketing function within the trial and devise robust systems for ensuring that the marketing (and later sales) activities are undertaken efficiently, effectively and in accordance with the values and goals of the trial.
1. To identify and describe the distinctive features of the 'segments' of the 'market' to be targeted.
2. To discover what people in each of the selected market segments value (i.e. what would encourage them to 'sign-up').
3. To develop a 'value proposition' (or more than one if required) that can be tested with each of the targeted segments.
4. To enrol the whole trial organisation in working within the trial's 'marketing brief'.
1. To convey, fully and persuasively, the 'value proposition' to sufficient numbers of people in the target market.
2. To convey, fully and persuasively, the 'value proposition' to intermediaries (e.g. doctors or nurses), influencing bodies (e.g. ethics committees) and other agents that can either help or hinder the conduct of the trial.
1. To learn, through doing, about 'the market'.
2. To utilise ongoing learning to develop more effective policies and practices.
3. To evaluate, and redirect the strategy of a trial as learning is acquired.
1. To maintain momentum by renewing or upgrading 'the offer' made to participants.
2. To sustain commitment of interested parties and other agencies whose support will be needed.
Clinical trials require strategy, management, marketing and sales. Undoubtedly they undertake the activities listed in the table 1 in some way. However, what happens if those who define the strategy of a trial, establish its management processes, devise its marketing plan and attempt to sell the benefits of participation try to improve their practice by explicitly engaging with the discipline of management? The study described below provides some preliminary answers to this question.
This study is a component of a three-part project – STEPS (Strategies for Trials Enrolment and Participation) . The first part included a quantitative analysis of the association between different patterns of recruitment in trials and factors thought likely to influence this pattern, based on an examination of Medical Research Council (MRC) and Health Technology Assessment (HTA) records . This showed recruitment often fails to meet targets. The second part explored these issues further using qualitative analysis of transcripts from semi-structured interviews with key players in four trials considered by MRC/HTA as exemplars , with a particular focus on the complexity of financial negotiations. Here we report the third part based on an in-depth investigation of a single trial from a business perspective to assess its marketing strategy, in order to develop a reference model to aid future trials.
The Corticosteroid Randomisation after Significant Head injury (CRASH) trial  was a large scale RCT of the effect of corticosteroids compared to placebo in improving important health outcomes . The trial aimed to recruit 20,000 head injured patients from hospitals world-wide. As the trial participants were unconscious the marketing strategy needed to focus on staff at participating hospitals (and not on the patients).
CRASH had a marketing challenge since it needed to engage the interest and collaboration of hundreds of people internationally, including members of ethics committees, surgeons, doctors, nurses and administrators. During the recruitment phase, one of us (DLF), a marketing and strategy specialist from the academic business sector, was invited to examine the trial as if it were a business, to comment on its marketing strategy and to help the trial team to understand and put in place a marketing plan over a two-year period. He was given access to all trial documents (apart from confidential investigators' personal details and patient data). He visited three participating hospitals in England, observed training sessions and interviewed or facilitated group discussions with doctors, nurses and ancillary staff. He also conducted 11 interviews, and held numerous meetings with members of the trial management team.
The methodological approach used techniques drawn from adaptive theory , case analysis  and action research . The researcher's interview notes were analysed using a grounded theory framework  and the emerging model was compared with data from studies in commercial enterprises. The N-Vivo qualitative analysis software program was used to structure data initially but manual analytic methods were used later as often the purpose was to highlight what participating agents were not saying – rather than what they were saying. A professor of management (independent of the study team) checked the interpretative framework against the raw data. Emerging results were presented to a peer group (the STEPS research team) and to the team members of the CRASH trial. A one-day marketing workshop using an action research approach was held with the trial team to provide insights into the extent to which concepts and practices from the business world  might have relevance to management of clinical trials. Early in 2004 an additional five-hour workshop was held with representatives from three trials (one of which was the CRASH trial) to gain further insight into the practical implications of the findings, providing a further opportunity to validate the researcher's theory building process.
As the approach reported in this paper was part of a strategy to try to improve recruitment into the CRASH trial, the STEPS investigators decided that separate ethics committee approval would not be required for this process as the CRASH trial had already received approval from the North London MREC.
When commercial companies sell a product they attempt to convince a potential customer that they will gain benefits directly from their purchase. In the CRASH the trial managers were seeking to gain a commitment to engage from clinical professionals who would make no material gain for themselves. Accordingly, the CRASH trial was selling an opportunity for clinical professionals to participate in improving future clinical practice – an activity that can be seen as being akin to a charitable endeavour . A challenge for the CRASH trial was to promote the idea that if a clinician signed up to the trial then medicine itself would progress and the clinician would be fulfilling a professional obligation.
A previously unexplored dimension of the marketing challenge was found to be the difficulty of gaining an evidence-based understanding the reasons why participants (in this case hospitals) signed up and what motivated them to fulfil a commitment that had no sanctions for non-performance. An analysis of feedback from participating hospitals concluded that they opted in for a variety of reasons, including the perceived merits of the study, the stature of the sponsors and advocates, the status provided to participants through participation and the affordability of participation (i.e how much time and effort would be required).
A tentative reference model was developed from the research date that facilitated an ongoing assessment of the sales and marketing capability of the trial.
The reference model
Ia) Developing brand values
Brand values define what a brand is and what it is not – i.e. its personality. A clinical trial can be seen as a brand. Without explicit brand values it is impossible to communicate a coherent and persuasive perception of a trial's promise – i.e. what the trial intends to deliver to medicine, doctors, patients etc.
Ib) Gaining legitimacy and prestige
Trials need legitimacy – they need to be positively tagged by association with prestigious individuals and institutions (so a hospital doctor may say, "I know that this is an important trial because Professor X, who I know and respect, is supporting it). Legitimacy and prestige provide persuasive credibility key to gaining access to decision-makers who decide whether a trial should be supported and maintain engagement.
Ic) Signalling worthiness
It is vital to signal to likely participants that, "this trial will create greater value than the costs (time, effort or money) involved". Buy-in is more likely to occur when participants realise, and identify with, the potential benefits that will be delivered by the success of the trial. Methods for doing this include presentations at conferences, journal publications, advertising, public relations and training materials.
IIa) Providing simple, complete processes
Trials require participants to undertake work that is additional to their normal duties. Providing simple, complete processes reduces the costs of participation and increases the chances that involvement will be affordable.
IIb) Devising strategies for overcoming resistance
Potential participants frequently raise objections. Trials should have standard and persuasive answers to these. Having a persuasive answer for each objection increases the probability of making a sale.
IIc) Adopting an explicit marketing plan
The marketing of a trial is too important and too complicated to be done informally. A formal marketing plan is required that should include a definition of target market segments (groups that need to buy in to the trial) and the trial's unique selling points (USPs). It is to be expected that the marketing plan will need to be revised frequently – probably every quarter. It can be useful to have separate plans for dealing with (1) The Uninformed (Inform and persuade with targeted stories), (2) The Unconvinced (Address concerns point-by-point – "get to yes"), (3) The Laggards (Enrol, cajole, facilitate and target), (4) The Steady Performers (Reward, renew, upgrade and recognise) and (5) The Stars (Honour, learn from, and nourish).
IIIa) Engaging active sponsors, champions and change agents
Selling a trial to prospective participants requires persuasion. This requires enrolling sponsors (public advocates), champions (activists) and change agents (facilitators). Trial managers need a network of supporters to spread the message. Persuasion is more likely to occur if the advocate is respected and known personally to the prospective participant.
IIIb) Delivering a multi-audience, multi-level message
Trials need to convey sales messages through publicity, presentations, training materials, etc. These should be tuned to the distinctive needs of target groups – for example, surgeons are likely to be persuaded by different messages than administrators or nursing staff. Speaking in the language of the person being targeted and addressing their particular pattern of motivation is more likely to succeed than a one size fits all approach.
IIIc) Achieving buy-in (in public)
Public buy-in requires that intended participants announce their commitment to join the trial in a setting where others hear them. This is important because when someone states, in public, that they are willing to undertake an action, then they are more likely to abide by their commitment than if they take a silent decision – that can be forgotten easily.
IVa) Ensuring positive moments of truth
People evaluate organisations (including trial management teams) on the basis of their experiences at moments of truth. For example, if a doctor has a technical question about entering a patient into a trial she will gain a strong impression of the trial management team's competence by the way that the query is handled. If trialists behave well in a moment of truth then loyalty grows; if not, loyalty diminishes.
IVb) Providing frequent positive reinforcement
Positive reinforcement for existing participants should be an important part of a trial's participant retention strategy. It is more expensive to recruit new participants than to retain existing participants.
IVc) Facilitating incorporation into routines
Activities that become embedded as routines are more likely to be done than one-offs. Trial procedures should be incorporated into the routines of units undertaking the work.
We found that the CRASH trial faced challenges in marketing and selling that were mission critical – i.e. if goals were not achieved then the trial would fail. Farrell, amongst others, has been arguing for a greater recognition of the role of management in the conduct of clinical trials . The key strength of the study reported here is that, for the first time in academic literature, it offers a reference model that provides a conceptual framework that can support and guide trial managers in assessing their marketing strengths and weaknesses 
The reference model described above should be seen as a tentative framework rather than a definitive template. It was developed from a theory-building process from a single trial and is best considered as a set of provocative hypotheses – later they may be developed as provisional audit tools. It may be that the reference model could be used as a diagnostic tool to identify if, and at what points, a trial is failing so that remedial interventions could be undertaken. An audit of the CRASH trial enabled components that were considered to be weaker than others to be identified and initiatives undertaken to improve in these areas. Further research is needed in other trials to explore whether the model is complete and correct and whether useful audit tools can be developed.
Clinical trials are not only research activities- they are also time-bound businesses that have two interdependent sets of processes – one clinical and the other managerial. In the main, since trials are seen as clinical endeavours, they are dominated by clinical issues and led by people with clinical skills. This is essential for certain policies and practices but this cultural bias can result in the managerial aspects of trials being, relatively, neglected. If this is true, even if only in part, it means that the radical improvement of clinical trials could require different ways of defining the challenges of running successful trials – in particular, to ensure that they are seen as management challenges that can benefit from the informed use of selected management processes and techniques.
These considerations suggest that looking within past trials for the answers to the problem of under-performing trials is necessary but will not be sufficient. In order to improve trials it will be necessary to look outside the world of clinical practice, into the worlds of business strategy, management, marketing and sales to gain a fuller understanding of what can be done to upgrade performance of clinical trials. This insight is not new. Donovan, Mills et al  state that the, "methodological literature (on trials) is almost exclusively statistical and epidemiological, and very little of it is concerned with the conduct or the particular demands that trials put on trialists and participants" (pp766).
This study could begin to change the ways that trial managers undertake their work. Also, it provides a different way to think about the skill sets and competencies needed by those who manage clinical trials. In essence, the message of this study is simple – even simplistic. It is that trials are both complex projects and businesses (they need to find customers). The key implication for clinicians is that insufficient attention to management issues and marketing or sales activities will degrade the performance of the trial.
There are significant implications for policy makers and funding bodies as well. If the tentative conclusions of this study are correct, then the funders will need to examine more than the scientific case before sponsoring a trial. They will need to see a marketing and sales plan, and be assured that all of the required elements of the business system will be developed. Since a successful trial requires both good science and good management, both need to be given their due weight.
But there are differences. Business is about profit. Medicine is driven by human values. It would be wrong to infer that publicly funded trials need to be more like businesses – rather, we suggest, that trials may benefit from using business concepts and business techniques.
This cross-disciplinary study was based on the premise that something new would be gained if a researcher from the world of business and management studied a clinical trial from his disciplinary perspective and worked with trialists to devise a useful framework. Since innovation is frequently facilitated by a clash of disciplines, it may be some of the insights needed to improve trial recruitment will come from fields other than medicine.
We would like to thank the National Co-ordinating Centre for Research Methodology for commissioning this research; the MRC and the DH for providing funding; and the CRASH trial team. The Health Services Research Unit is funded by the Chief Scientist Office of the Scottish Executive Health Department. The views expressed are not necessarily those of the funders and the funders had no involvement in the study.
- Lovato LC, Hill K, Hertert S, Hunninghake DB, Probstfield JL: Recruitment for Controlled Clinical Trials: Literature Summary and Annotated Bibliography. Controlled Clinical Trials. 1997, 18: 328-357. 10.1016/S0197-2456(96)00236-X.View ArticlePubMedGoogle Scholar
- Levitt T: Marketing Myopia. HBR. 1960, 45-56.Google Scholar
- McDonald M, Wilson H: The New Marketing: Transforming the Corporate Future. 2002, Oxford , Butterworth-HeinemannGoogle Scholar
- Schoenfeld ER, Greene JM, Wu SY, O'Leary E, Forte F, Leske C: Recruiting Participants for Community-Based Research: The Diabetic Retinopathy Awareness Program. AEP. 2000, 10 (7): 432-440.PubMedGoogle Scholar
- Farrell B: Efficient management of randomised controlled trials: nature or nurture. BMJ. 1998, 317: 1236-1239.View ArticlePubMedPubMed CentralGoogle Scholar
- Rowe JC, Elling ME, Hazlewood JG, Zakhary R: A Cure for Clinical Trials. McKinsey Quarterly. 2002Google Scholar
- Wilson J, Musick M: Who Cares? Towards An Integrated Theory Of Volunteer Work. American Sociological Review. 1997, 62: 694-713. 10.2307/2657355.View ArticleGoogle Scholar
- Campbell MK, Snowdon C, Francis D, Elbourne D, McDonald AM, Knight R, Entwistle V, Garcia J, Roberts I, Grant A, The STEPS Group: Recruitment to randomised trials: strategies for trial enrolment and participation study. The STEPS study. Health Technol Assess. 2007, 11 (48): 1-126.View ArticleGoogle Scholar
- McDonald AM, Knight RC, Campbell MK, Entwistle VA, Grant AM, Cook JA, Elbourne DR, Francis D, Garcia J, Roberts I, Snowdon C: What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. Trials. 2006, 7 (9):Google Scholar
- Snowdon C, Elbourne DR, Garcia J, Campbell MK, Entwistle VA, Francis D, Grant AM, Knight RC, McDonald AM, Roberts I: Financial considerations in the conduct of multi-centre randomised controlled trials: evidence from a qualitative study. Trials. 2006, 7 (34):Google Scholar
- Edwards P, Arango M, Balica L, Cottingham R, El-Sayed H, Farrell B: Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months. Lancet. 2005, 365 (9475): 1957-1959. 10.1016/S0140-6736(05)66552-X.View ArticlePubMedGoogle Scholar
- Roberts IG, Yates D, Sandercock P, Farrell B, Wasserberg J, Lomas G: Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet. 2004, 364 (9442): 1321-1328. 10.1016/S0140-6736(04)17188-2.View ArticlePubMedGoogle Scholar
- Layder D: Sociological Practice: Linking Theory and Social Research. 1998, London , SageView ArticleGoogle Scholar
- Yin R: Case Study Research: Design and Methods. 1994, Thousand Oaks, Cal , Sage, 2ndGoogle Scholar
- Eden C, Huxham C: Action Research. Essential Skills for Management Research. Edited by: Partington D. 2002, London , Sage Publications, 254-272.View ArticleGoogle Scholar
- Strauss A, Corbin J: Grounded Theory Methodology. Basics of Qualitative Research: Grounded Theory Procedures and Techniques. Edited by: Strauss A, Corbin J. 1990, Newbury Park, Cal , Sage, 273-285.Google Scholar
- Martindale D: Sociological Theory and the Ideal Type. Symposium on Sociological Theory. Edited by: Gross LL. 1959, Evanston, Illinois , Row, Peterson and Company, 57-91.Google Scholar
- Francis D, Woodcock M: Auditing Organizational Effectiveness. 2004, Farnborough , GowerGoogle Scholar
- Donovan J, Mills N, Smith M, Brindle L, Jacoby A, Peters T, Frankel S, Neal D, Hamdy F: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostrate testing for cancer and treatment) study. BMJ. 2002, 325: 766-769. 10.1136/bmj.325.7367.766.View ArticlePubMedPubMed CentralGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.